Firebird Biomolecular Sciences specializes in innovative reagents that enhance research, synthetic biology, and clinical diagnostics. Their flagship technology, the Artificially Expanded Genetic Information Systems (AEGIS), allows for the incorporation of additional genetic letters, enabling more complex genetic constructs. This technology is complemented by Self-Avoiding Molecular Recognition Systems (SAMRS), which facilitate unlimited multiplexing in molecular design. Additionally, Firebird offers Reversible Terminators, which are triphosphates designed to enable high-quality DNA sequencing and oligonucleotide synthesis by allowing reversible termination of oligonucleotide chains. Their Biversals technology addresses sequence divergence in PCR products, providing a versatile solution for managing variations in genetic sequences.

The company emphasizes cutting-edge innovation and high-quality results, supported by a state-of-the-art facility and unmatched expertise in the field. Firebird's products are designed to solve specific challenges faced in laboratories and clinical settings, making them valuable tools for researchers and clinicians alike. Their commitment to advancing synthetic biology and diagnostics is evident in their diverse product catalog, which includes a range of specialized reagents tailored to meet the evolving needs of the scientific community.

United States

Firebird Biomolecular Sciences, LLC. operates as a supplier of nucleic acid components, libraries, polymerases, and software to support human diagnostics, systhetic biology, and human therapy. The Company also offers naturally organized genomic databases, customized databases, and interpretive genomics services.

Firebird Biomolecular Sciences

Company Details